Top of this page
Skip navigation, go straight to the content
About UCB home
Passionate about enabling families with severe diseases to enjoy normal, everyday lives
Building the next generation biopharma leader
Discover how we are connecting patients, people and science in new ways to make radical breakthroughs in severe diseases
The power to make a difference
- A global biopharma focused on severe diseases with operations in more than 40 countries and global revenue of €3.6 billion in 2007
- A leader in allergy and epilepsy with 12 large and small molecules in the pipeline, spanning 16 diseases, from Crohn’s and Parkinson’s to multiple sclerosis.
- A leader in antibody research supported by proprietary chemistry and over 30 major R&D partners.
